ArticleImmuno-oncology technology2026
Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma.
Article in Immuno-oncology technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have transformed outcomes for advanced/metastatic melanoma and non-small-cell lung cancer (NSCLC), allowing for a growing population of ICI durable responders (ICI-DR). Despite improved survival, ICI-DR patients may face persistent health-related quality of life (HRQoL) challenges and these are poorly documented. The QUALICI study aimed to describe HRQoL and factors associated with better HRQoL outcomes, patients' experience, and expectations toward HRQoL in ICI-DR patients with advanced/metastatic NSCLC or melanoma. Patients and methods: QUALICI was a multicenter, cross-sectional study conducted in 16 French hospitals. All ICI-DR adults (≥2 years since ICI initiation, no subsequent cancer therapy) were screened and randomly selected to participate and complete questionnaires assessing HRQoL (EuroQol 5 Dimensions 5 Levels [EQ-5D-5L]), social difficulties [Social Difficulties Inventory (SDI)], fatigue (Chalder Fatigue Scale), and care experience. Results: A total of 234 patients (117 with NSCLC and 117 with melanoma) completed the questionnaires. Most patients (62.0% with NSCLC and 69.7% with melanoma) reported no/slight problems on the five EQ-5D-5L dimensions. Mean ± standard deviation (SD) visual analog scale scores were 67.0 ± 19.3 in the NSCLC group and 74.8 ± 19 in the melanoma group, with higher scores in younger and professionally active patients. Most patients (78.9% with NSCLC and 95.3% with melanoma) had moderate-to-severe fatigue and social difficulties were more pronounced in patients with NSCLC (mean ± SD SDI score: NSCLC 10.4 ± 8.5, melanoma 5.9 ± 6.6). Patients with moderate-to-severe problems on EQ-5D-5L had poorer perceived general health, increased fatigue, and more social difficulties in both groups. Two-thirds of patients had discussed quality of life issues with health care professionals yet 22.2% felt unable to fully express concerns. Conclusion: Most ICI-DR patients reported satisfactory HRQoL but heterogeneity and communication gaps support the need for patient-centered survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.